Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | SYNJ2 | O15056 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PPM1B | O75688 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24674068 | 1.00 | ALDH1A1 (0.58) | ALDH1A1HPGDPOLBGAAMAPK1 | |
| SCHEMBL24673603 | 1.00 | ALDH1A1 (0.58) | ALDH1A1HPGDPOLBGAAMAPK1 | |
| SCHEMBL22797615 | 1.00 | ALDH1A1 (0.58) | ALDH1A1HPGDPOLBGAAMAPK1 | |
| SCHEMBL24673839 | 0.88 | ALDH1A1 (0.45) | ALDH1A1HPGDPOLBGAAMAPK1 | |
| SCHEMBL22799523 | 0.85 | ALDH1A1 (0.53) | ALDH1A1HPGDPOLBGAAMAPK1 | |
| SCHEMBL22799896 | 0.85 | ALDH1A1 (0.53) | ALDH1A1HPGDPOLBGAAMAPK1 | |
| SCHEMBL24672886 | 0.81 | HPGD (0.38) | ALDH1A1HPGD | |
| SCHEMBL16063062 | 0.80 | ALDH1A1 (0.58) | ALDH1A1HPGDPOLBGAAMAPK1 | |
| SCHEMBL24673842 | 0.79 | ALDH1A1 (0.50) | ALDH1A1HPGDPOLBGAAMAPK1 | |
| SCHEMBL24673043 | 0.79 | ALDH1A1 (0.50) | ALDH1A1HPGDPOLBGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220275018-A1 | NOVEL SPIROBICYCLIC INTERMEDIATES | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-01 | — | — | US | disclosed |
| WO-2020249663-A1 | NOVEL SPIROBICYCLIC INTERMEDIATES | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275018-A1 | NOVEL SPIROBICYCLIC INTERMEDIATES | NME2, SLC28A1, SLC28A2 | ALDH1A1 248/4885HPGD 258/4885POLB 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.